These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2887995)

  • 21. (+/-)3,4-Methylenedioxymethamphetamine (MDMA) produces long-term reductions in brain 5-hydroxytryptamine in rats.
    Mokler DJ; Robinson SE; Rosecrans JA
    Eur J Pharmacol; 1987 Jun; 138(2):265-8. PubMed ID: 2887440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
    Schechter MD
    Pharmacol Biochem Behav; 1988 Dec; 31(4):817-24. PubMed ID: 2908067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity.
    Oberlender R; Nichols DE
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1098-106. PubMed ID: 1979813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of (+/-)-methylenedioxymethamphetamine and (+/-)-methylenedioxyamphetamine in monkeys trained to discriminate (+)-amphetamine from saline.
    Kamien JB; Johanson CE; Schuster CR; Woolverton WL
    Drug Alcohol Depend; 1986 Oct; 18(2):139-47. PubMed ID: 2877841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of conditioned taste aversions produced by MDMA and d-amphetamine.
    Lin HQ; Atrens DM; Christie MJ; Jackson DM; McGregor IS
    Pharmacol Biochem Behav; 1993 Sep; 46(1):153-6. PubMed ID: 7902981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of 3,4-methylenedioxymethamphetamine and related amphetamines on autonomic and behavioral thermoregulation.
    Jaehne EJ; Salem A; Irvine RJ
    Pharmacol Biochem Behav; 2005 Jul; 81(3):485-96. PubMed ID: 15904952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat.
    Johnson M; Letter AA; Merchant K; Hanson GR; Gibb JW
    J Pharmacol Exp Ther; 1988 Mar; 244(3):977-82. PubMed ID: 2472482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats.
    Callaway CW; Wing LL; Geyer MA
    J Pharmacol Exp Ther; 1990 Aug; 254(2):456-64. PubMed ID: 1974635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE; "EVE").
    Boja JW; Schechter MD
    Pharmacol Biochem Behav; 1987 Oct; 28(2):153-6. PubMed ID: 2891144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques.
    Crean RD; Davis SA; Von Huben SN; Lay CC; Katner SN; Taffe MA
    Neuroscience; 2006 Oct; 142(2):515-25. PubMed ID: 16876329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain.
    Gibb JW; Stone DM; Stahl DC; Hanson GR
    NIDA Res Monogr; 1987; 76():316-21. PubMed ID: 2449619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of MDMA ("Ecstasy") and its optical isomers on schedule-controlled responding in mice.
    Glennon RA; Little PJ; Rosecrans JA; Yousif M
    Pharmacol Biochem Behav; 1987 Feb; 26(2):425-6. PubMed ID: 2883666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat.
    Yamamoto BK; Spanos LJ
    Eur J Pharmacol; 1988 Mar; 148(2):195-203. PubMed ID: 2897922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDMA (3,4-methylenedioxymethamphetamine): proceedings of the conference. May 17-18, 1986, Oakland, California.
    J Psychoactive Drugs; 1986; 18(4):287-379. PubMed ID: 2880942
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites.
    Battaglia G; Brooks BP; Kulsakdinun C; De Souza EB
    Eur J Pharmacol; 1988 Apr; 149(1-2):159-63. PubMed ID: 2899513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective reduction of striatal type II glucocorticoid receptors in rats by 3,4-methylenedioxymethamphetamine (MDMA).
    Lowy MT; Nash JF; Meltzer HY
    Eur J Pharmacol; 1989 Apr; 163(1):157-61. PubMed ID: 2472965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MDMA as a discriminative stimulus: isomeric comparisons.
    Schechter MD
    Pharmacol Biochem Behav; 1987 May; 27(1):41-4. PubMed ID: 2886996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.
    Nichols DE
    J Psychoactive Drugs; 1986; 18(4):305-13. PubMed ID: 2880944
    [No Abstract]   [Full Text] [Related]  

  • 39. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Orally administered MDMA causes a long-term depletion of serotonin in rat brain.
    Finnegan KT; Ricaurte GA; Ritchie LD; Irwin I; Peroutka SJ; Langston JW
    Brain Res; 1988 Apr; 447(1):141-4. PubMed ID: 2898273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.